Articles Tagged With:
-
Early, goal-directed therapy of septic shock
One thousand two hundred sixty patients with early septic shock were randomized to early, goal-directed therapy vs. usual care. Hemodynamic management according to a strict protocol did not lead to an improvement in outcome.
-
Hospital wards with higher rates of antibiotic prescribing associated with increased risk for C. diff infection
A retrospective observational study found that among hospitalized patients, ward-level antibiotic prescribing was associated with a significantly increased risk for C. difficile infection beyond what would be expected with patient-level antibiotic use.
-
Vasospastic angina with myocardial infarction – more dangerous than once thought?
Patients with vasospastic angina and a type II myocardial infarction have a worse prognosis than previous believed.
-
Do I need atypical coverage for all non-ICU hospitalized patients with community-acquired pneumonia?
Is the accepted treatment for CAP enough, or could we do more?
-
Clinical Briefs
Updates on treatment of depression, the prevention and treatment of osteoporosis, and subclinical thyroid dysfunction as it relates to fracture risk.
-
Pharmacology Update: Memantine HCl and Donepezil HCl Capsules (Namzaric™)
The addition of memantine to a stable dose of an acetylcholinesterase inhibitor may improve cognitive performance.
-
PCSK9: A Major New Advance in Cholesterol-lowering Therapy
When added to statin therapy at the maximum tolerated dose, the PCSK9 inhibitor alirocumab reduced low-density lipoprotein cholesterol levels by 62% and also reduced the rate of occurrence of cardiovascular events.
-
Obesity Paradox and Diabetes
In a prospective cohort study of overweight or obese type 2 diabetics, being overweight was associated with a lower mortality risk, but being obese was not.
-
Can CPAP Treatment Prevent Dementia?
ABSTRACT & COMMENTARY: Older people with sleep apnea had onset of cognitive decline at an earlier age than those without sleep apnea.
-
Liletta: A New LNG-IUS Option
Initial clinical results with a new 52 mg levonorgestrel intrauterine system recently introduced to the market and approved for three years of use are similar to those seen with the existing system.